| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Net revenue | 17,631 | 16,413 | ||
| Cost of goods - (excluding amortization of acquired intangible assets) | 5,755 | 4,939 | ||
| Amortization of acquired intangible assets | 1,064 | 1,064 | ||
| Research and development | 208 | 8,126 | ||
| Selling, general and administrative | 17,415 | 38,757 | ||
| Total operating expenses | 24,442 | 52,886 | ||
| Loss from operations | -6,811 | -36,473 | ||
| Interest income | 736 | 622 | ||
| Gain from deconsolidation of subsidiary | - | 27,127 | ||
| Interest expense and financing fee | 2,742 | 2,518 | ||
| Gain (loss) on common stock warrant liabilities | -2 | -350 | ||
| Other income | 17,672 | -62 | ||
| Total other income (expense) | 15,664 | 24,819 | ||
| Income (loss) before income tax expense | 8,853 | - | ||
| Income tax expense (refund) | 26 | - | ||
| Net income (loss) | 8,827 | -11,654 | ||
| Attributable to non-controlling interests | 2,977 | -27,140 | ||
| Net income (loss) attributable to fortress | 5,850 | 15,486 | ||
| Preferred a dividends declared and paid and/or cumulated, and fortress' share of subsidiary deemed dividends | 2,174 | - | ||
| Net income (loss) attributable to common stockholders | 3,675 | - | ||
| Earnings per share, basic | 0.13 | 0.5 | ||
| Earnings per share, diluted | 0.11 | 0.45 | ||
| Weighted average number of shares outstanding, basic | 27,244,474 | 26,879,380 | ||
| Weighted average number of shares outstanding, diluted | 33,100,961 | 29,824,182 | ||
Fortress Biotech, Inc. (FBIOP)
Fortress Biotech, Inc. (FBIOP)